Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk : role of protease inhibitor exposure.

Hurwitz BE, Klimas NG, Llabre MM, Maher KJ, Skyler JS, Bilsker MS, McPherson-Baker S, Lawrence PJ, Laperriere AR, Greeson JM, Klaus JR, Lawrence R, Schneiderman N.

Cardiovasc Toxicol. 2004;4(3):303-16.

PMID:
15470277
3.

Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.

Jones R, Sawleshwarkar S, Michailidis C, Jackson A, Mandalia S, Stebbing J, Bower M, Nelson M, Gazzard BG, Moyle GJ.

HIV Med. 2005 Nov;6(6):396-402.

4.
5.

HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.

Rose H, Woolley I, Hoy J, Dart A, Bryant B, Mijch A, Sviridov D.

Metabolism. 2006 Jan;55(1):90-5.

PMID:
16324925
6.

Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease.

Holvoet P.

Verh K Acad Geneeskd Belg. 2008;70(3):193-219. Review.

PMID:
18669160
7.

Postprandial response to a physiologic caloric load in HIV-positive patients receiving protease inhibitor-based or nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Thomas-Geevarghese A, Raghavan S, Minolfo R, Holleran S, Ramakrishnan R, Ormsby B, Karmally W, Ginsberg HN, El-Sadr WM, Albu J, Berglund L.

Am J Clin Nutr. 2005 Jul;82(1):146-54.

8.

Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?

Klein D, Hurley LB, Quesenberry CP Jr, Sidney S.

J Acquir Immune Defic Syndr. 2002 Aug 15;30(5):471-7.

PMID:
12154337
9.

[HIV infection, antiretroviral therapy, and endothelium].

Hürlimann D, Weber R, Enseleit F, Lüscher TF.

Herz. 2005 Sep;30(6):472-80. Review. German.

PMID:
16170677
10.

Ritonavir-boosted protease inhibitors, Part 2: cardiac implications of lipid alterations.

Cohen CJ.

AIDS Read. 2005 Oct;15(10):528-32, 537-8. Review.

PMID:
16265768
11.

Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.

Young J, Rickenbach M, Weber R, Furrer H, Bernasconi E, Hirschel B, Tarr PE, Vernazza P, Battegay M, Bucher HC.

Antivir Ther. 2005;10(1):73-81.

PMID:
15751765
12.

Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women.

Floris-Moore M, Howard AA, Lo Y, Arnsten JH, Santoro N, Schoenbaum EE.

HIV Med. 2006 Oct;7(7):421-30.

13.

Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors.

Hiransuthikul N, Hiransuthikul P, Kanasook Y.

Southeast Asian J Trop Med Public Health. 2007 Jan;38(1):69-77.

PMID:
17539249
14.

Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy.

Moreno-Torres A, Domingo P, Pujol J, Blanco-Vaca F, Arroyo JA, Sambeat MA.

Antivir Ther. 2007;12(2):195-203.

PMID:
17503662
15.
16.

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.

Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E; SWAN Study Group.

Clin Infect Dis. 2007 Jun 1;44(11):1484-92. Epub 2007 Apr 25.

PMID:
17479947
17.

Coronary artery calcium in HIV-infected men treated with highly active antiretroviral therapy.

Robinson FP, Hoff JA, Kondos GT.

J Cardiovasc Nurs. 2005 May-Jun;20(3):149-54.

PMID:
15870584
18.

Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.

Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ.

Pharmacotherapy. 2008 Mar;28(3):323-30. doi: 10.1592/phco.28.3.323.

PMID:
18294112
19.

Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs.

Correll CU, Frederickson AM, Kane JM, Manu P.

J Clin Psychiatry. 2006 Apr;67(4):575-83.

PMID:
16669722
20.

Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study.

Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, Chmiel JS, Visscher BR, Margolick JB, Dobs AS.

AIDS. 2005 Sep 2;19(13):1375-83.

PMID:
16103768

Supplemental Content

Support Center